Want to see HK:1875 full AI Analyst Report?
1875 Stock Chart & Stats
HK$2.50
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$2.50
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.70 - HK$5.87
Previous CloseN/A
Volume400.00
Average Volume (3M)240.51K
Market Cap
HK$2.48B
Enterprise ValueHK$1.99K
Total Cash (Recent Filing)HK$328.47M
Total Debt (Recent Filing)HK$383.72M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding772,787,900
10 Day Avg. Volume141,880
30 Day Avg. Volume240,506
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.60
Price to Sales (P/S)2.18
P/FCF Ratio-60.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.40Price Target Upside76.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.18
Revenue Forecast (FY)HK$566.06M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsA dual business model (own-product sales plus CDMO/CMO services) provides durable revenue diversification. CDMO contracts can generate recurring service fees and steady utilization, while product sales offer upside from commercial adoption, reducing single-source revenue risk over months.
Manageable Leverage And Capital BaseRelatively modest debt levels versus equity signal financial flexibility for a biotech with lumpy cash needs. Manageable leverage supports continued R&D and manufacturing investment and provides capacity to absorb revenue volatility without immediate solvency pressure over the medium term.
In-house GMP Manufacturing CapabilitiesOwning GMP manufacturing and development expertise is a durable competitive advantage: it lowers time-to-market for internal assets, attracts CDMO customers, and creates high switching costs. This vertical capability supports margin resilience and long-term partner relationships.
Bears Say
Sharp 2025 Revenue DeclineA ~32% revenue drop in 2025 indicates weakening commercial traction or lost sales that can persist without clear recovery drivers. Reduced scale undermines fixed-cost absorption in manufacturing and R&D, worsening unit economics and constraining reinvestment for growth over coming quarters.
Persistently Negative Free Cash FlowChronic negative FCF limits the company's ability to self-fund development and capacity expansion. Over the medium term this increases dependency on external financing, which can dilute shareholders or raise financing costs and constrain strategic optionality during down cycles.
Volatile Profitability And Margin CompressionSwinging from profit to loss and compressed gross margins signal unstable pricing, mix, or cost control. Persistent earnings volatility makes long-term planning harder, can deter partners and investors, and raises the risk that future investments may not generate expected returns.
TOT BIOPHARM International Co. Ltd. News
1875 FAQ
What was TOT BIOPHARM International Co. Ltd.’s price range in the past 12 months?
TOT BIOPHARM International Co. Ltd. lowest stock price was HK$1.70 and its highest was HK$5.87 in the past 12 months.
What is TOT BIOPHARM International Co. Ltd.’s market cap?
TOT BIOPHARM International Co. Ltd.’s market cap is HK$2.48B.
When is TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date?
TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 15 days.
How were TOT BIOPHARM International Co. Ltd.’s earnings last quarter?
TOT BIOPHARM International Co. Ltd. released its earnings results on Mar 18, 2026. The company reported -HK$0.148 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is TOT BIOPHARM International Co. Ltd. overvalued?
According to Wall Street analysts TOT BIOPHARM International Co. Ltd.’s price is currently Undervalued.
Does TOT BIOPHARM International Co. Ltd. pay dividends?
TOT BIOPHARM International Co. Ltd. does not currently pay dividends.
What is TOT BIOPHARM International Co. Ltd.’s EPS estimate?
TOT BIOPHARM International Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TOT BIOPHARM International Co. Ltd. have?
TOT BIOPHARM International Co. Ltd. has 772,787,900 shares outstanding.
What happened to TOT BIOPHARM International Co. Ltd.’s price movement after its last earnings report?
TOT BIOPHARM International Co. Ltd. reported an EPS of -HK$0.148 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.695%.
Which hedge fund is a major shareholder of TOT BIOPHARM International Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1875
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TOT BIOPHARM International Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.65%
Trailing 12-Months
Company Description
TOT BIOPHARM International Co. Ltd.
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key product candidates, including TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009, and its primary base of operations is situated in Suzhou, China.
1875 Stock 12 Month Forecast
Average Price Target
HK$4.40
▲(76.00% Upside)
Technical Analysis
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Lepu Biopharma Co. Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
Shanghai Henlius Biotech, Inc. Class H
―